ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / BBIO / news
JAZZ (49) ASND (69) SMMT (40) RDY (64) ⌘ Pro Terminal →

Why BBIO Stock advanced +0.06% Today — RQD Quant Desk Flash

$75.00 +0.06% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $74.87

BridgeBio Pharma Inc. (BBIO) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $14.60B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BBIO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BBIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, BridgeBio Pharma Inc. (NASDAQ: BBIO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $75.00 (+0.06% 1D, market cap $14.60B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BBIO ranks #618 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BBIO compare to JAZZ and ASND in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BBIO carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 95.8%, and ROIC of -35.0%. By comparison, JAZZ (Jazz Pharmaceuticals plc (Ireland)) holds a D grade (49/100 RQD, P/E N/A, ROIC -4.7%, cap $14.02B) and ASND (Ascendis Pharma A/S Ordinary Share) posts a C+ grade (69/100 RQD, P/E 32.8x, ROIC 9.9%, cap $16.55B). Among the 5-stock peer group, ASND leads on earnings multiple (32.8x) while ASND leads on capital efficiency (9.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BBIO?
▼

Per BBIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001743881), BridgeBio Pharma Inc. generated $502.1M in revenue (+126.3% YoY), $0 in net income, and -$447.0M in free cash flow against $936.0M in total assets and $1.36B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $74.86 (-0.18%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510034
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk E
Cash (3)Whales (14)SEC (5)Macro (7)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-10.8% Base Target
$98 Bull$67 Base$52 Bear
📬 FREE BBIO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BBIO)Realized 20D OHLCV Swing Band: ±6.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY BBIO SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (41% of score)

20D Institutional Volume Accumulation (±6.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (21% of score)

FRED Regime × Technicals: 45% of 52W Range • RSI-14 at 63.9 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
26
Grade E$64.94+4.3% Next Q
Q2 (-2Q)
29
Grade E$67.74+4.5% Next Q
Q3 (-1Q)
31
Grade E$70.82+5.9% Next Q
Current
34
Grade E$75.00-8.7% Hist 90D α
Trajectory: E (26) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BBIO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BBIO currently carries a cautious 34/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($69.74) and Max Pain ($78.75) forces dealer call-delta covering toward $98.09.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BBIO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BBIO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 34%NO 66%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why BBIO Stock advanced +0.06% Today — RQD Quant Desk Flash

BridgeBio Pharma Inc. (BBIO) advanced +0.06% to $75.00, trading at 45% of its 52-week range ($60.22 – $93.42). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 45% of its 52-week range ($60.22 – $93.42) with RSI-14 at 63.9 (BULLISH MOMENTUM).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±6.5% around $75.00 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 95.8% gross margin and $0 annual free cash flow.
Live BBIO Headlines & Catalysts
RISK WATCHYahoo Finance • 1d ago
What BridgeBio Pharma Doubters Missed

Yahoo Finance report covering BridgeBio Pharma Inc. (BBIO) market action, institutional positioning, and fundamental catalysts.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BBIO)

  • ✓Walkthrough of BBIO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
BBIO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +8.71%⚡ TESTING RESISTANCE
2026-11-03O $70.73H $75.00L $70.73C $75.00VOL 5.77M
RES: $75.13SUP: $62.35SMA50: $69.74SMA200: $72.68
$95.58$86.62$77.65$68.68$59.72RES $75.13SUP $62.35$75.002026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BBIO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BBIO Butterfly Map → + Track BBIO →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
25.5%/yr Implied 5Y Growth

vs. +126.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BBIO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BBIO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BBIO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BBIO)

Health Care Rank #618 of 1015 ⚔️ JAZZ vs BBIO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BBIO vs. JAZZ, ASND, SMMT, RDY)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, BridgeBio Pharma Inc. (BBIO) ranks #618 by composite RQD confidence (34/100, grade E) and #81 by equity capitalization ($14.60B). Within this direct 5-issuer industry benchmark cohort, ASND leads on earnings valuation at 32.8x trailing P/E, while ASND leads on capital efficiency and profitability with 9.9% ROIC and — gross margin. ASND currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with BBIO at 34/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BBIO ACTIVE
BridgeBio Pharma Inc.
E 34/100 — 95.8% -35.0% +0.06% $14.60B Benchmark Subject
JAZZ
Jazz Pharmaceuticals plc (Ireland)
D 49/100 — — -4.7% -0.71% $14.02B /jazz-vs-bbio →
ASND
Ascendis Pharma A/S Ordinary Share
C+ 69/100 32.8x — 9.9% -0.91% $16.55B /asnd-vs-bbio →
SMMT
Summit Therapeutics Inc.
D- 40/100 — — -35.0% -7.67% $12.82B /smmt-vs-bbio →
RDY
Dr. Reddy's Laboratories Ltd
C 64/100 32.8x — 9.9% -0.28% $11.83B /rdy-vs-bbio →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001743881 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), BridgeBio Pharma Inc. (BBIO) reported GAAP revenue of $502.1M (+126.3% vs. FY2024 revenue of $221.9M , and +5296.9% cumulative change since FY2023) , GAAP net income of $0, operating cash flow of -$445.9M, and free cash flow of -$447.0M (+14.3% YoY). On the balance sheet, BBIO closed FY2025 with $936.0M in total assets against $1.36B in total debt (Altman Z-Score: 0.45, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $502.1M $0 -$445.9M -$447.0M $936.0M $1.36B
FY2024 (FY) 2024-12-31 $221.9M $0 -$520.7M -$521.7M $919.3M $437.3M
FY2023 (FY) 2023-12-31 $9.3M $0 -$527.7M -$528.1M $7.60B $1.78B

3. BBIO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BBIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, BridgeBio Pharma Inc. (NASDAQ: BBIO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $75.00 (+0.06% 1D, market cap $14.60B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BBIO ranks #618 in composite RQD confidence.

How does BBIO compare to JAZZ and ASND in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BBIO carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 95.8%, and ROIC of -35.0%. By comparison, JAZZ (Jazz Pharmaceuticals plc (Ireland)) holds a D grade (49/100 RQD, P/E N/A, ROIC -4.7%, cap $14.02B) and ASND (Ascendis Pharma A/S Ordinary Share) posts a C+ grade (69/100 RQD, P/E 32.8x, ROIC 9.9%, cap $16.55B). Among the 5-stock peer group, ASND leads on earnings multiple (32.8x) while ASND leads on capital efficiency (9.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BBIO?

Per BBIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001743881), BridgeBio Pharma Inc. generated $502.1M in revenue (+126.3% YoY), $0 in net income, and -$447.0M in free cash flow against $936.0M in total assets and $1.36B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BBIO trading relative to its 50-day, 200-day, and 52-week technical levels?

BBIO last traded at $75.00 (+0.06% on volume of 3,097,274 shares), positioning the stock +7.54% above its 50-day simple moving average ($69.74) and +3.19% above its 200-day simple moving average ($72.68). Across its 52-week range of $60.22 to $93.42, BBIO sits at the 44.5% percentile with a 14-day RSI of 63.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.5% ($70.12 to $79.88).

Direct Sub-Reports: BBIO RQD Cockpit BBIO 12M Forecast BBIO Earnings & Move BBIO Dividends & DRIP BBIO Insiders & 13F BBIO Whale Options BBIO Profit Sankey BBIO News & Why
ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

BBIO — BridgeBio Pharma Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

BridgeBio Pharma Inc. (BBIO) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $75.00 (+0.06% 1D, market capitalization $14.60B).

  • Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 95.8%, operating margin of -60.0%, and free cash flow yield of -3.23%.
  • Whale 13F & Options Flow (14/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.45, Piotroski F-Score of 4/9, and Debt/Equity of 0.85x.

2. Business Model, Unit Margins & SEC Financial Trajectory

BridgeBio Pharma Inc. Is a NASDAQ-listed company classified under the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. The company reported revenue of $502.1M in FY 2025, up from $221.9M in FY 2024 and $9.3M in FY 2023.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), BridgeBio Pharma Inc. (BBIO) reported $502.1M in annual revenue (up from $221.9M in FY2024, +126.3% YoY) and $0 in GAAP net income. Over the multi-year SEC filing window from FY2023 ($9.3M revenue, $0 net income) through FY2025, BBIO scaled operating cash flow to -$445.9M and free cash flow to -$447.0M, backed by $936.0M in total assets against $1.36B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -3.23% and institutional whale pillar of 14/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 14/20, sustained execution supports upside toward the upper end of the $60.22 – $93.42 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), BBIO carries a macro regime beta of 1.00 and gross margin of 95.8%.

  • Key Question #1: Can BBIO sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $502.1M and free cash flow of -$447.0M, how will capital allocation balance growth reinvestment against $1.36B in total debt?
  • Key Question #3: How sensitive is BBIO's 33.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BBIO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for BridgeBio Pharma Inc. (BBIO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BBIO Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BBIO Bull vs. Bear Conversation Board — What's Your Call at $75.00?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BBIO 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BBIO:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $95.19 (+27.0%)
📌 Pinned Debate

Institutional accumulation and options positioning score 12/20, the strongest pillar, alongside reported positive Phase 3 trial results

Institutional accumulation and options positioning score 12/20, the strongest pillar, alongside reported positive Phase 3 trial results in the news feed.. When you look under the hood at BBIO, Fundamental Cash Engine is 3/20 with 95.8% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (14/20) has been quietly accumulating below $93.42. My 12M target is $95.19.

RetailWhale_TX 🐂 BULL

@BearTrap_Alert Shorting a 14/20 institutional whale-flow stock at $74.95 is dangerous when funds are rotating into Health Care.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $62.21 (-17.0%)
Spot @ $74.95

Negative ROIC of -35%, FCF of -$447.0M, Altman Z of 0.45, and debt rising to $1.36B against falling cash signal substantial forensic

Negative ROIC of -35%, FCF of -$447.0M, Altman Z of 0.45, and debt rising to $1.36B against falling cash signal substantial forensic and cash-generation risk.. Look at the math on BBIO: paying 33.0x forward P/E for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $65.96 before getting long.

LIVE TAPE